Home News

News

ImmunoGen Initiates Pivotal Trial Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Biotech company ImmunoGen, leveraging the targeting ability of antibodies to deliver cytotoxic drugs directly to cancer cells by developing...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality ADC

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the...

IND for RemeGen’s Disitamab Vedotin Marks Important Milestone for the Company’s First US-based Clinical...

The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application allowing Yantai (Shandong Province;...
The AACR Annual Meeting in better times - before COVID19: the AACR annual meeting opening plenary session in 2018 at the McCormick Convention Center in Chicago, Illinois with the 2019 president-elect Elaine Mardis, Ph.D, who served as program committee chair for this 2018 meeting, addressed attendees. Photo Courtesy © AACR/Todd Buchanan.

AACR 2020: Phase I Clinical Trial with STRO-002 Shows Encouraging Interim Dose-escalation Data...

Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going...

FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients...

Netherlands Based Precision Medicines Developer Relaunches as Byondis

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate...
HPAPI Lab at Abzena. Photo Courtesy: 2019 Abzena.

Addressing the Challenges of Bioconjugate Medicines

The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates,...

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy

Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more...

Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation Study; Raises U.S....

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers...

Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as First-Line Treatment for...

Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle...